Select year

2026 2025 2024 2023 2022 Earlier

shown/page

10

2021.12.01

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

2021.04.16

Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)
Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)

2021.01.11

Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N
Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N

2020.12.16

Chipscreen and HISUN reach a strategic cooperation
Chipscreen and HISUN reach a strategic cooperation

2020.06.24

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

2020.03.24

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

2019.12.03

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication

2019.10.09

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development
Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

2019.09.20

Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted
Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted

2018.05.30

Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center
Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com